Pulmonary syndrome and intravenous high-dose desferrioxamine. 1990

A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D013789 Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. Thalassemias

Related Publications

A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
January 1992, Haematologica,
A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
July 1983, Lancet (London, England),
A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
May 1981, Israel journal of medical sciences,
A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
January 1986, Acta haematologica,
A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
January 1996, American journal of hematology,
A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
December 2010, Pediatric blood & cancer,
A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
October 1988, Annals of neurology,
A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
July 1989, American journal of hematology,
A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
February 1989, European journal of pediatrics,
A Castriota Scanderbeg, and G C Izzi, and A Butturini, and G Benaglia
March 2008, Pediatric cardiology,
Copied contents to your clipboard!